

MicroRNA-7 directly targets *Reg1* in pancreatic cells

Shawna Downing^{1¶}, Fan Zhang^{1¶}, Zijing Chen¹, Emmanuel S. Tzanakakis^{1,2*}

¹Department of Chemical and Biological Engineering, Tufts University, Medford, MA 02155

²Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA 02111

[¶]Equal contribution

Running title: *MicroRNA-7 regulates Reg1 expression*

• Shawna Downing, Graduate Student, Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, Shawna.Downing@tufts.edu

• Fan Zhang, Graduate Student, Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, Fan.Zhang@tufts.edu

• Zijing Chen, Graduate Student, Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, Zijing.Chen@tufts.edu

• Emmanuel S. Tzanakakis, Professor, Chemical and Biological Engineering, Tufts University, Medford, MA, 02155, Emmanuel.Tzanakakis@tufts.edu

* Corresponding author:

Emmanuel S. Tzanakakis

Professor

Department of Chemical and Biological Engineering

Tufts University

Science and Technology Center, Room 276A

Medford, MA 02155 USA

Phone: +1-617-627-0831

Fax: +1-617-627-3991

E-mail address: Emmanuel.Tzanakakis@tufts.edu

29
30
31
32
33
34
35
36
37
38
39
40
41

List of abbreviations

- 3'UTR: 3' untranslated region
- AD: Alzheimer disease
- EGFR: Epidermal growth factor receptor
- hfPCR: high fidelity polymerase chain reaction
- PanIN: pancreatic intraepithelial neoplasia
- PDAC: pancreatic ductal adenocarcinoma
- PMSF: phenylmethanesulfonyl fluoride
- PVDF: polyvinylidene difluoride

Abstract

Regenerating islet-derived (Reg) proteins, which were first discovered in the pancreas, are associated with increased proliferation, prevention of apoptosis and enhanced differentiation in normal and disease states but very little is known about the regulation of their expression. We hypothesized that Reg expression is influenced by microRNAs. Bioinformatic analysis predicted Reg1 to be a target of microRNA-7 (miR-7), which influences pancreatic beta-cell function. To this end, we investigated the effects of miR-7 on Reg1 expression in pancreatic acinar and islet beta-cells. High levels of Reg1 were noted by immunostaining and western blotting in acinar cells in contrast to islet cells. A reciprocal expression pattern was observed for miR-7. Overexpression of miR-7 resulted in Reg1 mRNA suppression and reduction of secreted Reg1 protein. Conversely, miR-7 knockdown led to increases in Reg1. Targeting of Reg1 by miR-7 was confirmed via luciferase activity assays. In contrast, miR-7 did not directly repress the human ortholog of Reg1, REG1A, as well as REG1B indicating species differences in the regulation of Reg expression. This is the first account of microRNA modulation of any Reg member warranting studies to fill gaps in our knowledge of Reg protein biology, particularly in disease contexts.

Keywords: Reg proteins; microRNA-7; pancreas; islets; acinar cells.

60 **Introduction**

61 Regenerating islet-derived (Reg) proteins are C-type lectin-like proteins originally discovered in patients
62 with chronic calcific pancreatitis (10) while subsequent studies linked Regs further to pancreatitis (5, 22, 32) but
63 also to pancreatic cancer and diabetes. In particular, murine Reg1 and its human ortholog REG1A (also known
64 as lithostathine) are expressed in the exocrine pancreas and hyperplastic islets but not in normal islets.
65 Transgenic mice expressing Reg1 from a glucagon promoter in their islets exhibit apoptosis of β -cells with
66 ensuing diabetes and develop malignant tumors (48). Yet, Reg1 helps restore β -cell mass after pancreatectomy
67 in rats (43) and prevents or delays the development of diabetes in non-obese diabetic mice (44). Elevated
68 plasma Reg1 has been observed in mice with pancreatic intraepithelial neoplasia (PanIN) lesions (16), while
69 REG1A and REG1B are detected in the serum and urine of pancreatic ductal adenocarcinoma (PDAC) patients
70 (30, 39). Reg1 has also been implicated in extrapancreatic pathologies including colon cancer (49), seminoma
71 (33), hepatocellular carcinoma (8), cholangiocarcinoma (21) and Alzheimer disease (AD) (11, 12).

72 Despite the protein's significant presence in various pathophysiological contexts, especially as they relate to
73 pancreas, very little is known about the regulation of the Reg1 gene expression. Miscellaneous factors including
74 IL-6 and dexamethasone (13), PDGF and growth hormone (19), and gastrin (3) reportedly influence Reg1 levels
75 in different cell types, partly through pertinent response elements on the gene promoter. Beyond autocrine or
76 paracrine signals, regulation of protein production or RNA stability can be mediated by microRNAs (miRNA),
77 which are short (18-25 nucleotides) single-stranded RNA molecules that cleave or translationally repress their
78 specific target gene mRNAs (7). MicroRNA-modulated gene expression underlies diverse cellular processes
79 including proliferation, apoptosis, differentiation and tumorigenesis. To this end, several microRNAs regulate
80 pancreatic cell function, metabolism and differentiation. However, no miRNA has been identified to date that
81 targets Reg genes in any cell type including pancreatic cells.

82 Here, we performed bioinformatic analysis of the 3' untranslated region (3'UTR) of the Reg1 mRNA
83 seeking miRNAs with matching seed regions. The *mmu-miR-7a-5p* and *mmu-miR-7b-5p* featuring identical

seed regions were among the miRNAs identified as potentially targeting the murine *Reg1* mRNA. The aforementioned miRNAs belong to a group comprising *Mir7a-1*, *Mir7a-2* and *Mir7b* (9) all of which have the same seed sequence. The miR-7 family is evolutionary conserved across primates, rodents, and zebrafish exhibiting a neuroendocrine pattern of expression (4, 6, 9, 28, 47). In the adult rat and human pancreases, the islet/acinar tissue ratio of miR-7 expression is greater than 200 (6, 9, 26). Transgenic mice overexpressing miR-7a in β -cells develop diabetes due to impaired insulin secretion and β -cell dedifferentiation without significant changes in proliferation and apoptosis (29). In humans, miR-7 is also downregulated in PDAC and ampullary adenocarcinoma compared to normal pancreas (41).

Given the apparent inverse localization of miR-7 and *Reg1* in the pancreatic acinar and islet compartments, we considered the possibility of miR-7 targeting *Reg1* thereby influencing its expression in line with our *in silico* analysis. Here, we show that miR-7 is a negative regulator of the murine *Reg1*. The repression of *Reg1* by miR-7 was observed in acinar cells and β -cells. Further, the human *REG1A* (homolog of the murine *Reg1*) and *REG1B* are not direct targets of miR-7, pointing to differences among species in the determinants of *Reg* expression. This is the first account of miRNA modulation of the expression of a member of the *Reg* protein family.

Materials and Methods

Housing and care of mice and collection of pancreatic tissues were approved by the Institutional Animal Care and Use Committee at Tufts University.

Murine pancreatic islet and exocrine tissue isolation

Isolation of pancreatic tissue was performed as we reported (50). Eight-week old C57/BL6 mice were injected intraperitoneally with 270 mg/kg ketamine/15 mg/kg xylazine (anesthesia overdose). A cannula was prepared by filling with collagenase solution (CIZyme, Vitacyte, Indianapolis, IN) a syringe fitted with a 27 G

needle. After an incision made in the lower abdomen (V cut), the pancreas was exposed, the pancreatic duct was clamped off at its duodenal insertion with a small bulldog clamp and the cannula was inserted into the duct proximal to the liver. Collagenase solution (3 ml/mouse) was injected to fully inflate the pancreas, which was subsequently removed and placed in a 50-ml conical tube for 20-30 min in a 37°C water bath. At the end of the incubation, RPMI 1640 medium with 10% FBS was added (~20 ml) to each tube. The tubes were hand shaken vigorously for 5-10 seconds to break up the tissue and were kept in ice. Samples were washed three times to remove the collagenase by centrifugation at 180xg for 1.5 min. The supernatant was poured off, medium was added (~25 ml) and the samples were vortexed gently. The suspension was filtered through a 400-µm wire mesh (VWR, Randor, PA). The filtrate containing islets and exocrine tissue was spun at 180xg for 1.5 min and the supernatant was removed. The pellet was resuspended in 10-15 ml Histopaque 1077 (Sigma-Aldrich, St. Louis, MO) and vortexed until the suspension was homogeneous. After overlaying with 10 ml of RPMI 1640 medium the sample was spun for 20 min at 1750xg with very slow acceleration and no braking at 10°C. Islets were collected from the interface with a 10-ml serological pipette and placed in a 50-ml conical tube. Exocrine tissue was collected from the bottom of the gradient and harvested to 50 ml-conical tubes. After three washes with RPMI 1640 with 10% FBS and centrifugation at 180xg for 1.5 min the islet fraction was transferred to 6-cm sterile culture dishes for islet picking under a microscope (Leica Microsystems Inc., Buffalo Grove, IL). Islet and the exocrine tissue were immediately processed for total RNA extraction or immunohistochemistry (see pertinent section below).

Cloning and Vector Preparation

The murine miR-7 (*mmu-miR-7a-2*) and 3'UTR of *Reg1* were cloned by high fidelity PCR (hfPCR) from genomic DNA isolated from MIN6 cells. The following primers were utilized: *mmu-miR-7a-2*; forward (F): 5'-ATATAGATCTGAAGGTGGCTAGCGTGA-3', reverse (R): 5'-CCCGTCGACTGAAATGACCAGCAC-3' (underlined: *Bgl*III and *Sal*I sites). The miR-7 inhibitor (miR-7 sponge) sequence was designed (14) with two repeats of the miR-7 binding site: 5'-ACAACAAAATCACTAGTCTTCCA-3' and generated by hfPCR using

134 overlapping primers. The microRNA-67 from *C. elegans* (*cel-miR67*; accession MI0000038) was also included
135 in the study as an unrelated microRNA control. The corresponding synthesized DNA (Eurofins Genomics,
136 Louisville, KY) was used as a template for hfPCR amplification with the primers: (F) 5'-
137 GGAGATCTATTCCAACCTCGATCA-3', R: 5'-CCGTCGACAATAAACGAAATT-3' (underlined: *Bgl*III and
138 *Sall* sites). The amplification product of miR-7, miR-7 inhibitor, or cel-miR-67 was ligated into the
139 pSuper.GFP/neo vector (Oligoengine, Seattle, WA) between the *Bgl*III and *Sall* sites (pSuper.GFP/neo-miR-7).

140 The murine *Reg1* 3'UTR was cloned from MIN6 cell genomic DNA using the primers: F: 5'-
141 GGGAATTCAGTCACCTGAAAAAAATAGTCA-3', R: 5'-CCACTAGTGCAACATTGTAAAGGTGT-3'
142 (underlined: *Eco*RI and *Spe*I sites). Genomic DNA was also extracted from human embryonic kidney 293
143 (HEK293) cells for cloning the 3'UTRs of *REG1A* and *REG1B* with the primers: *REG1A* 3'UTR; F: 5'-
144 GGGAATTCAGGCAACTGGAAAATACATG-3', R: 5'-CCACTAGTGACAGCACAATAGTGGAAAC-3',
145 and *REG1B* 3'UTR; F: 5'-GGGAATTCAGGAAGCTGAAAAATGGATGT-3, R: 5'-
146 CCACTAGTGAGCAAATGCAGAAGACAGAA-3' (underlined: *Eco*RI and *Spe*I sites). The pGL3 luciferase
147 vector (Promega, Madison, WI) was modified by (i) replacing the CMV promoter with the EF1 α promoter and
148 (ii) inserting a multiple cloning site (MCS) segment in the *Xba*I site flanking the 3' end of the luciferase gene.
149 The MCS contained restriction sites for *Eco*RI and *Spe*I for insertion of the 3'UTR of *Reg1* (Luc-3'UTR-Reg1),
150 *REG1A* or *REG1B*. A mutated *Reg1* 3'UTR sequence ($^{97}\text{-GTCTTCC}^{-103} \rightarrow ^{97}\text{-GTCCCTT}^{-103}$; +1 denoting the
151 nucleotide immediately after the *Reg1* stop codon) was generated by high-fidelity PCR using a corresponding
152 synthesized template (Integrated DNA Technologies, Coralville, IA) and was inserted in the above luciferase
153 vector (Luc- Δ 3'UTR-Reg1) as described for the wild-type *Reg1* 3'UTR. All constructs were verified by
154 sequencing.

155

156 *Cell culture and transfection*

157 MIN6 and β TC β -cells, 266-6 acinar cells (ATCC, Manassas, VA) and HEK293 cells were cultured in
158 DMEM medium (Thermo Fisher Scientific) with 10% fetal bovine serum (FBS) and penicillin-streptomycin

159 (100 U/ml – 50 µg/ml). Cells were manually passaged every 5-7 days with TrypLE (Life Technologies,
160 Carlsbad, CA) at a 1:4-1:6 ratio, and media were replaced every 3-4 days. The cultures were maintained in 5%
161 CO₂/95% air at 37 °C. Cells were stained with Trypan Blue dye (Life Technologies) and counted in a
162 hemocytometer or with the TC20 automated cell counter (Bio-Rad, Hercules, CA).

163 For transfection, cells were grown to 70-90% confluence and plasmids were delivered using Lipofectamine
164 2000 (Invitrogen). Transfection of miR7 (C-310592-07) or cel-miR67 (CN-001000-01) mimic (Dharmacon
165 Inc., Lafayette, CO) was carried out with RNAiMax (Invitrogen, Carlsbad, CA) following the manufacturer's
166 instructions.

167

168 *RNA extraction, RT-PCR and quantitative PCR analysis*

169 Total cellular RNA was extracted with Trizol (Life Technologies) according to manufacturer's instructions.
170 Reverse transcription was performed at 42 °C for 60 min with 1 µg total RNA using ImProm-II reverse
171 transcriptase (Promega, Madison, WI) and 250 ng oligo(dT)₁₂₋₁₈ primers (Thermo Fisher Scientific). The
172 reverse transcriptase was heat-inactivated at 70 °C for 15 min. The resulting complimentary DNA (cDNA) was
173 analyzed on a StepOne Plus thermocycler (Applied Biosystems, Foster City, CA) by quantitative PCR (qPCR)
174 for 40 cycles and 58-60 °C annealing temperature depending on each primer set. The sequences for primers
175 used in this study are listed in **Table 1**.

176 For miRNA expression analysis, total RNA was converted to cDNA with the qScript microRNA cDNA
177 synthesis kit (Quantabio, Beverly, MA) using an oligo-dT adapter primer (**Table 1**). The resulting cDNA was
178 amplified by qPCR (PerfeCTa SYBR Green SuperMix, Quantabio) with a universal PCR primer combined with
179 a primer targeting the *mmu-mir7a-5p* or the *RNU6-2*.

180 Analysis was performed based on the $\Delta\Delta C_T$ method (17) with *Actb* and *RNU6-2* used as endogenous
181 controls for the expression of *Reg1* and *mmu-mir7a-5p*, respectively.

182

183 *Immunocytochemistry*

Cells were fixed in 4% paraformaldehyde (Sigma-Aldrich) for 20 min and permeabilized with 0.1% Triton X-100 in PBS for 20 min at room temperature (nuclear marker staining). After three 5-min washes with PBS after each step, samples were blocked with 3% normal donkey serum (NDS; Jackson ImmunoResearch Laboratories Inc., West Grove, PA) in PBS for 30 min. Incubation was carried out at 4 °C with a sheep anti-murine Reg1 antibody (AF1657; R&D Systems, Minneapolis, MN) followed by treatment with a donkey anti-sheep Rhodamine Red-X-conjugated antibody (713-295-147; Jackson ImmunoResearch) at room temperature for 1 h. Nuclear DNA was stained with DAPI (Sigma-Aldrich). Controls were stained with IgG instead of primary antibody. Immunostaining was visualized with a Leica TCS SPE confocal microscope (Leica Microsystems Inc., Buffalo Grove, IL).

Immunohistochemistry

Paraffin-embedded sections were dehydrated with increasing concentrations of ethanol (80–100%). After three 15-min washings with PBS, samples were blocked for 20 min in 3% NDS at 37°C and then incubated overnight at 4°C with guinea pig anti-murine insulin (A0564; Dako/Agilent Technologies, Carpinteria, CA) and sheep anti-murine Reg1 primary antibodies. Following three more washes with PBS, the sections were incubated with AffiniPure donkey anti-guinea pig Alexa Fluor 488 and anti-sheep Rhodamine Red-X (706-545-148 and 713-295-147, respectively; Jackson ImmunoResearch) secondary antibodies for 30 min at 37°C. The samples were then washed three times with PBS, mounted with SlowFade Diamond Antifade medium containing DAPI (Invitrogen) and visualized by confocal microscopy.

Western blot analysis

Total protein was isolated using lysis buffer containing Tris-HCl (50 mM, pH 8), NaCl (150 mM), NP40 (1%), sodium dodecyl sulfate (SDS) (0.1%), sodium deoxycholate (1%), protease inhibitor cocktail including PMSF, and phosphatase inhibitors (1 mM sodium fluoride, 5 mM sodium pyrophosphate, 5 mM sodium orthovanadate; all from Sigma-Aldrich). Protein concentration was determined via the Bradford method (Pierce

Biotechnology, Rockford, IL). Samples were separated in 10% SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes as described before (25). The membranes were blocked with 5% skim milk and incubated overnight at 4 °C with diluted primary antibodies against murine Reg1 (1:1,000) and β -actin (1:1,000; #4970, Cell Signaling Technology, Beverly, MA). Then, membranes were washed four times (10-min) with TBST and incubated for 1 h at room temperature with corresponding horseradish peroxidase (HRP)-linked secondary antibodies (1:10,000; 713-035-147, 711-035-152, Jackson ImmunoResearch). After further washing with TBST, enhanced chemiluminescence reagent (Pierce Biotechnology) was added and the membranes were visualized with a C-DiGit blot scanner (LI-COR Biotechnology, Lincoln, NE). Densitometry was performed using the Image Studio software (LI-COR) (42).

Dual Luciferase Assay

For determination of luciferase activity, cells in 24-well plates were transfected with a total of 500 ng of plasmids per well as stated. Luciferase activity was assessed using the Dual Luciferase Assay Kit (Promega, Madison, WI) 24-72 h post-transfection. Luminescence was detected in a microplate reader (Spectramax i3x, Molecular Devices, San Jose, CA) with firefly luciferase activity normalized to the respective *Renilla* luciferase signal for each sample.

Enzyme immunosorbent assay (ELISA)

ELISA was performed to detect protein secreted in the culture medium. Cells were grown to 70-90% confluence and the medium was replaced by low-serum medium (DMEM with 1% FBS). After 30 h, the medium was collected and cells were harvested with TrypLE (Life Technologies, Carlsbad, CA) and resuspended in fresh medium. Cells were counted using a hemocytometer while the collected medium was added to 96-well EIA/RIA plates (Corning Inc, Corning, NY). Fresh low-serum medium served as control. Recombinant murine Reg1 (R&D Systems) was plated at different dilutions to obtain a standard curve as we reported (25). After overnight incubation at 4°C wells were coated with a blocking buffer of 3% BSA and 0.1%

azide in 0.1% TBST for 90 min at 37°C. Following four washes with 0.1% TBST, samples were incubated for 2 h at room temperature with biotinylated sheep anti-mouse Reg1 (1:2000; BAF1657, R&D Systems) diluted in buffer of 0.1% TBST with 1% BSA and 0.1% azide. Wells were again washed four times and a secondary rabbit anti-biotin antibody (#5597, Cell Signaling Technology) in the same dilution buffer was added for 1 h at room temperature. The wells were washed 4 times with 0.1% TBST and incubated with 1-StepTM Ultra TMB-ELISA substrate solution (Thermo Fisher Scientific) per manufacturer's instructions. Total Reg concentration was normalized by the number of cells in each sample.

Statistical analysis

Data are expressed as mean \pm standard deviation (SD) unless stated otherwise from at least three independent experiments analyzed in triplicates. ANOVA and the *posthoc* Tukey test were performed using Prism (v. 8, GraphPad Software, La Jolla, CA). Values of $p < 0.05$ were considered as significant.

Results

Murine Reg1 is a predicted target of miR-7

We set out to search *in silico* for miRNAs with binding sites on the 3'UTR of the murine *Reg1*. Interrogation of the TargetScan database (1) revealed several putative miRNAs targeting *Reg1* (**Table 2**). Of those miRNAs, the seed region of miR-7a-5p and miR-7b-5p was an exact match for the 97-103 nucleotide segment of the 3'UTR of *Reg1* (**Fig. 1A**). Given the involvement of the miR-7 family in pancreatic cell function and pathologies (15, 29), we decided to further investigate its potential role on the expression of murine Reg1.

Of note, we found no putative binding site(s) for miR-7 in the 3'UTR sequences of the genes encoding the human REG1A (Reg1 ortholog) and REG1B proteins despite the miR-7 family being conserved in mice and humans and the high homology between the murine and human Reg proteins.

Reciprocal expression of Reg1 and miR-7 in murine pancreatic exocrine and islet cells

259 We proceeded to investigate experimentally whether *Reg1* is a target of *miR-7*. First, the expression profiles
260 of *Reg1* and *miR-7* were established by examining both exocrine cells and islet β -cells. Higher levels of *miR-7*
261 were detected in MIN6 (7.08-fold, $p=0.0164$) and β TC β -cells (44.46-fold, $p=0.009$) than in 266-6 acinar cells
262 (**Fig. 1B**). This *miR-7* expression pattern was mirrored in murine primary islets (30.08-fold, $p=5\times 10^{-4}$) and
263 exocrine tissue.

264 Conversely, *Reg1* expression was lower in β -cells than in 266-6 cells (MIN6: 26.9-fold lower, β TC: 12.4-
265 fold lower, both with $p<10^{-4}$). Similarly, primary islets exhibited lower *Reg1* levels (4.97-fold, $p=7\times 10^{-4}$)
266 compared to exocrine explants (**Fig. 1C**). Moreover, 266-6 cells were positive for *Reg1* unlike MIN6 cells (**Fig.**
267 **2A**) and *Reg1* was detected in exocrine regions but not in islets of pancreatic tissue sections (**Fig. 2B**). These
268 findings were corroborated by Western blotting (**Fig. 2C**). Secreted *Reg1* protein was present in supernatants
269 from 266-6 cell cultures but was not detectable in those from MIN6 and β TC cells (**Fig. 2D**).

270 Taken together, these findings demonstrate that increased *miR-7* expression coincides with lower levels of
271 *Reg1* in β -cells and primary islets while these profiles are inverted in exocrine cells.

273 *Direct targeting of murine Reg1 by miR-7*

274 The reciprocal expression of *Reg1* and *miR-7* in exocrine and endocrine cells along with the discovery *in*
275 *silico* of a region of the *Reg1* 3'UTR matching the *miR-7* seed sequence prompted us to investigate whether
276 *miR-7* represses *Reg1* directly. To this end, *miR-7* was overexpressed or suppressed so that *Reg1* levels could
277 be analyzed. Overexpression of *miR-7* (transfection with *miR7 OE* plasmid) led to a 60% reduction of *Reg1*
278 expression (**Fig. 3A**; $p=5.5\times 10^{-3}$, $n=3$) in 266-6 cells. Accordingly, the amounts of *Reg1* released in the medium
279 were greater in control cells than in those overexpressing *miR-7* (**Fig. 3B**). The content of *Reg1* in the latter
280 cells (*miR7 OE*) was almost half (**Figs. 3C-D**) of that of cells transfected with *cel-miR67*. The *cel-miR-67* was
281 chosen because (i) it is natively expressed in *C. elegans* reducing the risk for confounding interactions with
282 murine cell miRNA moieties, and (ii) there are no apparent sites on the 3'UTR of *Reg1* matching the *cel-miR-*
283 *67* seed region. The expression of *cel-miR-67* did not affect *Reg1* or *miR-7* levels. Upon inhibition of *miR-7* in

MIN6 cells, which natively exhibit pronounced *miR-7* levels, *Reg1* expression was increased (**Fig. 3A**) but there was no detectable change in Reg1 protein (**Fig. 3E**). Similarly, overexpression of *miR-7* resulted in reduction of *Reg1* mRNA. These results show that the constructs used in this study were effective for *miR-7* modulation. More importantly, augmenting or suppressing *miR-7* levels causes significant changes in Reg1.

Direct repression of the expression of a gene by a particular microRNA involves binding of the latter to the 3'UTR of the target mRNA. Therefore, the 3'UTR of *Reg1* was placed downstream of the luciferase gene (Luc-3'UTR-Reg1). When Luc-3'UTR-Reg1 was delivered with a *miR-7* mimic to 266-6 cells, luciferase activity was lower supporting the notion that *miR-7* directly interacts with the 3'UTR of *Reg1* (**Fig. 4A**). No differences were noted in luciferase activity between cells treated with *cel-miR67* mimic or vehicle. Furthermore, 266-6 cells were co-transfected with the *miR-7* overexpression plasmid and either the Luc-3'UTR-Reg1 vector or a luciferase construct with the *Reg1* 3'UTR but with its *miR-7* binding site mutated (Luc-Δ3'UTR-Reg1). Despite overexpression of *miR-7*, luciferase signal was significantly reduced only in Luc-3'UTR-Reg1-transfected cells (**Fig. 4B**). Again, co-expression of *cel-miR67* with either of the aforementioned luciferase constructs did not result in differences in luciferase activity in comparison to cells receiving the empty expression vector.

These results prove that *miR-7* directly targets the 3'UTR of murine *Reg1* in line with the bioinformatic analysis-based identification of *Reg1* as a *miR-7* target.

Human REG1A and REG1B are not targets of miR-7

We also assessed whether the human REG1A (ortholog of murine Reg1) and REG1B, which together comprise the human REG1 subgroup, are also targeted by *miR-7*. Cells were transfected with a construct containing the luciferase gene upstream of the 3'UTR of the human *REG1A* (Luc-3'UTR-REG1A) or *REG1B* (Luc-3'UTR-REG1B). Additionally, these cells were co-transfected either with the *miR-7* OE or empty (control) vector. There was no difference in luciferase activity in 266-6 cells receiving each luciferase vector regardless of the expression of *miR-7* (**Fig. 5A**).

The findings support our *in silico* analysis indicating the absence of regions matching the miR-7 seed on the *REG1A* and *REG1B* 3'UTRs.

Discussion

Regulation of the expression of Reg family members remains puzzling despite their discovery almost four decades ago. This is surprising considering that Reg proteins are implicated in major pathologies of the pancreas and other tissues including the gastrointestinal tract and central nervous system. Here, we showed that miR-7 directly targets the murine *Reg1* modulating its expression. This is aligned with the reciprocal expression of miR-7 and Reg1 in the acinar and islet cells although the physiological significance of this pattern is unclear.

Both miR-7 and Reg1 influence the differentiation and proliferation of β -cells. Overexpression of *Mir-7a* in murine islets causes a decline in β -cell differentiation markers such as *Pdx1*, *Nkx6-1*, *Mafa* and *Neurod1* whereas pancreatic islets of *Rip-Cre Mir7a2^{fl/fl}* mice exhibit higher steady-state levels of these transcripts compared to controls (29). MiR-7 expression drops during islet compensation at the onset of diabetes in BKS *db/db* mice (29). MiR-7 also regulates adult β -cell proliferation negatively as it targets five components of the mTOR signaling pathway (46). In contrast, Reg1 is considered a β -cell mitogen with its expression increasing in regenerating or hyperplastic islets although the exact mechanism is unknown (24, 45). Delayed development of diabetes and larger islet volume are observed in the offspring of NOD mice crossed with transgenic mice overexpressing *Reg1* from an insulin promoter (*Ins-Reg*) (44). After damage due to encephalomyocarditis virus infection, the islets of *Reg1^{-/-}* mice exhibit lower BrdU labeling compared to those of wild-type mice (2). Moreover, diabetic NOD mice exposed to human REG1A display a greater β -cell mass than control animals (20). When combined with our findings of miR-7 targeting Reg1, a picture emerges of potentially coordinated Reg1/miR-7 activities. Further investigation will be necessary to determine if these activities have significant implications in the physiology for pancreatic cells. It will be particularly interesting to examine if control of murine β -cell proliferation by miR-7 may partly be realized through adjustment of Reg1 expression.

332 Expression of Reg1 has been detected in E9-E12 mouse embryos but not in E8.5 and Reg2, which exhibits a
333 76% amino acid homology with Reg1, appears on E12 (37). Conversely, miR-7 expression is low between
334 E10.5-11.5 and increases at E13.5-E14.5 with strong localization in pancreatic endocrine cells and the neural
335 tube (34). Of note, the *Reg2* 3'UTR exhibits no matching regions for the miR-7 seed based on bioinformatic
336 analysis. This is in line with the restricted expression of Reg2 mRNA and protein in the exocrine tissue (40).
337 Hence, the upregulation in Reg2 may compensate the repression of Reg1 due to rising miR-7 levels but the
338 functional equivalence of Reg2 and Reg1 (despite their high amino acid homology) is not established.

339 It should be noted that the profile of Reg1 has not been studied in miR-7 mutant mice. As discussed already,
340 deletion of *Mir7a2* in the islets of *Rip-Cre Mir7a2^{fl/fl}* mice led to improved glucose tolerance via increased
341 insulin secretion (29). However, the available gene expression data (GSE48195) are not sufficient for
342 comprehensive statistical analysis to determine specific changes in *Reg1* levels. Moreover, mice with
343 conditional excision of miR-7a-2 exhibit a reduction – but not complete ablation – of miR-7 expression most
344 likely due to compensatory effects by other miR-7 family members (36). Hence, information about the
345 relationship between Reg1 and miR-7 *in vivo* has been challenging to obtain from published studies involving
346 miR-7 transgenic mice. This is further exacerbated by the plurality of miR-7 target genes.

347 Inhibition of miR-7 in β -cells resulted in increased *Reg1* expression but no changes were detected in the
348 corresponding protein. A longer period of miR-7 suppression may be necessary for a substantial change in the
349 protein level while additional mechanisms influencing the production of Reg protein cannot be ruled out.

350 The interaction between miR-7 and Reg1 may also be appreciated in other contexts beyond pancreas
351 pathophysiology. MiR-7 is expressed in various regions of the brain of humans and mice (18, 28) and is linked
352 to neuronal differentiation and function while its dysregulation may contribute to neurological disorders,
353 including AD (38). To this end, aged animals have lower Reg1 expression than healthy animals in a murine
354 model of AD (31). Hence, addressing whether miR-7 affects the expression of Reg1 in this context similar to
355 what we have demonstrated in pancreatic cells is of significant interest. Similarly, Reg1 and miR-7 have been

implicated in different types of cancer in studies involving rodent models (23, 27, 35) opening prospects for further investigation of the Reg1/miR-7 relationship as a contributing factor.

We found that miR-7 directly targets the murine *reg1* but not the human *REG1A* and *REG1B*. Other genes also have miR-7 target sites in their 3'UTR that are poorly conserved among species. The human epidermal growth factor receptor (*EGFR*) gene features two segments targeted by miR-7 in its 3'UTR whereas the murine *Egfr* has a single 3'UTR region albeit with low similarity to the miR-7 seed (23). In fact, overexpression of miR-7 does not alter *Egfr* expression in MIN6 cells (46). The difference we report here between the murine Reg1 and the human REG1A and REG1B may underlie yet unknown disparities among species in the regulation of Reg and therefore in its function in normal and disease states. It also cautions about extrapolating findings on Reg proteins from studies involving rodents to humans. Nonetheless, the discovery of the modulation of a Reg family gene in murine cells by a miRNA motivates the exploration of a similar mechanism applicable to human Reg genes. To this end, ongoing work focuses on the identification of miRNAs targeting the human Reg members that may potentially lead to novel insights into Reg protein biology.

Acknowledgements

Funding support has been provided by the National Science Foundation (NSF, CBET1743367) to EST.

Author Contributions

F. Zhang, S. Downing and Z. Chen performed research; F. Zhang, S. Downing, Z. Chen and E. Tzanakakis analyzed data; F. Zhang, S. Downing and E. Tzanakakis wrote the paper; E. Tzanakakis designed research.

Figure Legends

Figure 1. (A) Alignment of a putative miR-7 binding sequence in the murine *Reg1* 3'-UTR (nucleotides 97–103) is shown with the seed regions (capital letters) of mmu-miR-7a-5p and mmu-miR-7b-5p. Expression of (B) *mmu-miR-7* and (C) *Reg1* in MIN6 and β TC β -cells as well as primary islets and exocrine tissue. * $p < 0.05$,

381 ** $p < 0.01$ vs. the expression of 266-6 cells (for MIN6 and β TC β -cells) or exocrine tissue (for islets) from $n = 4$
382 separate experiments analyzed in triplicates. Normalization of *mmu-miR-7* and *Reg1* data was performed
383 relative to the expression of *RNU6-2* and *Actb*, respectively.

384
385 **Figure 2.** (A) Immunocytochemistry of 266-6 and MIN6 cells for Reg1. Nuclear DNA staining (DAPI) is also
386 shown along with merged images. Control samples (middle row) were stained only with the secondary
387 antibody. Bars: 25 μ m. (B) Reg1 protein expression in pancreatic tissue. Insulin expression demarcates islet β -
388 cells. Bars: 50 μ m. (C) Western blot for the expression of Reg1 in 266-6, MIN6, and β TC cells. The loading
389 control beta-actin (*Actb*) is also shown. L: ladder. (D) The concentration of Reg1 secreted in the culture
390 medium was determined by ELISA ($n = 3$ experiments in triplicates), ND: not detectable.

391
392 **Figure 3.** (A) Relative *Reg1* expression in 266-6 and MIN6 cells transfected with either a *miR-7* overexpression
393 (OE) or inhibition (sponge; SP) plasmid. Results from cells transfected with a plasmid for an unrelated control
394 microRNA (*cel-miR67*) are included. * $p < 0.05$, $n = 3$ experiments vs. *Reg1* levels for cells transfected with empty
395 vector. The *miR-7* levels after transfection with *miR7* SP or *cel-miR67* plasmid are shown. * $p < 0.05$, $n = 3$
396 experiments vs. *miR7* expression for cells transfected with empty vector. (B) ELISA results showing the
397 amounts of Reg1 released by 266-6 cells transfected with either an empty vector (Control) or the *miR-7* OE
398 plasmid. * $p < 0.05$, $n = 3$ experiments in triplicates. (C) A representative blot is shown of Reg1 content in 266-6
399 cells transfected with an *cel-miR7* or *miR-7* OE plasmid. A MIN6 cell sample is also shown. Loading control:
400 *Actb*. (D) Results of densitometric analysis of western blots such as the one shown in (C). The results are the
401 average ($n = 3$) values of the ratio of intensities of the Reg1 and corresponding *Actb* bands for each 266-6 cell
402 sample shown in (C). * $p < 0.05$ vs. cells transfected with the *cel-miR67* plasmid. (E) Western blot for Reg1 from
403 266-6 and MIN6 cells transfected with either the empty miRNA expression vector (pSuper) or *miR-7* sponge
404 (*miR7* SP). The loading control, *Actb*, is also shown.

Figure 4. (A) Acinar 266-6 cells were transfected with a luciferase vector featuring the 3'UTR of Reg1 (Luc-3'UTR-Reg1) and incubated with various concentrations of miR-7 or cel-miR-67 mimic before measuring luciferase activity. Results are shown as relative activity compared to cells treated with vehicle only (0 nM). * $p < 0.0001$ vs. cells transfected with cel-miR67 mimic at the same concentration, $n = 4-7$ independent experiments in triplicates. (B) Luciferase activity was reduced with overexpression of miR-7 (miR7 OE, light bars) in cells co-transfected with Luc-3'UTR-Reg1 but not in those with the luciferase vector carrying the 3'UTR of Reg1 with a scrambled seed region (Luc- Δ 3'UTR-Reg1). Dark bars depict results of cells transfected with an empty vector. * $p < 0.0001$, $n = 3$ experiments. No differences were noted in cells transfected with each of the aforementioned luciferase vectors and the cel-miR67 plasmid (hatched bars).

Figure 5. *miR7* does not target the 3'UTR of human REG1A and REG1B. Luciferase activity results are shown for 266-6 cells from $n = 3$ independent experiments with triplicate measurements.

References

1. Agarwal V, Bell GW, Nam JW, and Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 4: 2015.
2. Aida K, Kobayashi T, Takeshita A, Jimbo E, Nishida Y, Yagihashi S, Hosoi M, Fukui T, Sugawara A, and Takasawa S. Crucial role of Reg I from acinar-like cell cluster touching with islets (ATLANTIS) on mitogenesis of beta cells in EMC virus-induced diabetic mice. *Biochem Biophys Res Commun* 503: 963-969, 2018.
3. Ashcroft FJ, Varro A, Dimaline R, and Dockray GJ. Control of expression of the lectin-like protein Reg-1 by gastrin: role of the Rho family GTPase RhoA and a C-rich promoter element. *Biochem J* 381: 397-403, 2004.

- 429 4. **Ason B, Darnell DK, Wittbrodt B, Berezikov E, Kloosterman WP, Wittbrodt J, Antin PB, and**
430 **Plasterk RH.** Differences in vertebrate microRNA expression. *Proceedings of the National Academy of*
431 *Sciences of the United States of America* 103: 14385-14389, 2006.
- 432 5. **Bimmler D, Schiesser M, Perren A, Scheele G, Angst E, Meili S, Ammann R, and Graf R.**
433 Coordinate regulation of PSP/reg and PAP isoforms as a family of secretory stress proteins in an animal model
434 of chronic pancreatitis. *J Surg Res* 118: 122-135, 2004.
- 435 6. **Bravo-Egana V, Rosero S, Molano RD, Pileggi A, Ricordi C, Dominguez-Bendala J, and Pastori**
436 **RL.** Quantitative differential expression analysis reveals miR-7 as major islet microRNA. *Biochem Biophys Res*
437 *Commun* 366: 922-926, 2008.
- 438 7. **Bushati N, and Cohen SM.** microRNA functions. *Annu Rev Cell Dev Biol* 23: 175-205, 2007.
- 439 8. **Cavard C, Terris B, Grimber G, Christa L, Audard V, Radenen-Bussiere B, Simon MT, Renard**
440 **CA, Buendia MA, and Perret C.** Overexpression of regenerating islet-derived 1 alpha and 3 alpha genes in
441 human primary liver tumors with beta-catenin mutations. *Oncogene* 25: 599-608, 2006.
- 442 9. **Correa-Medina M, Bravo-Egana V, Rosero S, Ricordi C, Edlund H, Diez J, and Pastori RL.**
443 MicroRNA miR-7 is preferentially expressed in endocrine cells of the developing and adult human pancreas.
444 *Gene Expr Patterns* 9: 193-199, 2009.
- 445 10. **De Caro A, Lohse J, and Sarles H.** Characterization of a protein isolated from pancreatic calculi of
446 men suffering from chronic calcifying pancreatitis. *Biochem Biophys Res Commun* 87: 1176-1182, 1979.
- 447 11. **de la Monte SM, Ozturk M, and Wands JR.** Enhanced expression of an exocrine pancreatic protein in
448 Alzheimer's disease and the developing human brain. *The Journal of clinical investigation* 86: 1004-1013, 1990.
- 449 12. **Duplan L, Michel B, Boucraut J, Barthelémy S, Desplat-Jego S, Marin V, Gambarelli D, Bernard**
450 **D, Berthezene P, Alescio-Lautier B, and Verdier JM.** Lithostathine and pancreatitis-associated protein are
451 involved in the very early stages of Alzheimer's disease. *Neurobiol Aging* 22: 79-88, 2001.

13. **Duseti NJ, Mallo GV, Ortiz EM, Keim V, Dagorn JC, and Iovanna JL.** Induction of lithostathine/reg mRNA expression by serum from rats with acute pancreatitis and cytokines in pancreatic acinar AR-42J cells. *Arch Biochem Biophys* 330: 129-132, 1996.
14. **Ebert MS, Neilson JR, and Sharp PA.** MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. *Nat Methods* 4: 721-726, 2007.
15. **Esguerra JL, Bolmeson C, Cilio CM, and Eliasson L.** Differential glucose-regulation of microRNAs in pancreatic islets of non-obese type 2 diabetes model Goto-Kakizaki rat. *PloS one* 6: e18613, 2011.
16. **Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, Katayama H, Glukhova V, Phanstiel D, Brenner DE, Anderson MA, Misek D, Scholler N, Urban ND, Barnett MJ, Edelstein C, Goodman GE, Thornquist MD, McIntosh MW, DePinho RA, Bardeesy N, and Hanash SM.** A mouse to human search for plasma proteome changes associated with pancreatic tumor development. *PLoS Med* 5: e123, 2008.
17. **Fan Y, Hsiung M, Cheng C, and Tzanakakis ES.** Facile engineering of xeno-free microcarriers for the scalable cultivation of human pluripotent stem cells in stirred suspension. *Tissue engineering Part A* 20: 588-599, 2014.
18. **Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, Burge CB, and Bartel DP.** The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. *Science* 310: 1817-1821, 2005.
19. **Francis PJ, Southgate JL, Wilkin TJ, and Bone AJ.** Expression of an islet regenerating (reg) gene in isolated rat islets: effects of nutrient and non-nutrient growth factors. *Diabetologia* 35: 238-242, 1992.
20. **Gross DJ, Weiss L, Reibstein I, van den Brand J, Okamoto H, Clark A, and Slavin S.** Amelioration of diabetes in nonobese diabetic mice with advanced disease by linomide-induced immunoregulation combined with Reg protein treatment. *Endocrinology* 139: 2369-2374, 1998.

475 21. **Harada K, Zen Y, Kanemori Y, Chen TC, Chen MF, Yeh TS, Jan YY, Masuda S, Nimura Y,**
476 **Takasawa S, Okamoto H, and Nakanuma Y.** Human REG I gene is up-regulated in intrahepatic
477 cholangiocarcinoma and its precursor lesions. *Hepatology* 33: 1036-1042, 2001.

478 22. **Hayakawa T, Naruse S, Kitagawa M, Nakae Y, Harada H, Ochi K, Kuno N, Kurimoto K, and**
479 **Hayakawa S.** Pancreatic stone protein and lactoferrin in human pancreatic juice in chronic pancreatitis.
480 *Pancreas* 10: 137-142, 1995.

481 23. **Horsham JL, Ganda C, Kalinowski FC, Brown RA, Epis MR, and Leedman PJ.** MicroRNA-7: A
482 miRNA with expanding roles in development and disease. *Int J Biochem Cell Biol* 69: 215-224, 2015.

483 24. **Ishii C, Kawazu S, Tomono S, Ohno T, Shimizu M, Kato N, Fukuda M, Ito Y, Kurihara S, Murata**
484 **K, and Komeda K.** Appearance of a regenerating (reg) gene protein in pancreatic islets of remission
485 BB/Wor//Tky rats. *Endocr J* 40: 269-273, 1993.

486 25. **Jing D, Kehoe DE, and Tzanakakis ES.** Expression of Reg family proteins in embryonic stem cells
487 and its modulation by Wnt/beta-catenin signaling. *Stem Cells Dev* 19: 1307-1319, 2010.

488 26. **Joglekar MV, Joglekar VM, and Hardikar AA.** Expression of islet-specific microRNAs during
489 human pancreatic development. *Gene Expr Patterns* 9: 109-113, 2009.

490 27. **Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A, Priebe W, and Giraud**
491 **AS.** Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. *Plos One* 9:
492 e95993, 2014.

493 28. **Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A, Pfeffer S, Rice A, Kamphorst AO,**
494 **Landthaler M, Lin C, Socci ND, Hermida L, Fulci V, Chiaretti S, Foa R, Schliwka J, Fuchs U, Novosel A,**
495 **Muller RU, Schermer B, Bissels U, Inman J, Phan Q, Chien M, Weir DB, Choksi R, De Vita G, Frezzetti**
496 **D, Trompeter HI, Hornung V, Teng G, Hartmann G, Palkovits M, Di Lauro R, Wernet P, Macino G,**
497 **Rogler CE, Nagle JW, Ju J, Papavasiliou FN, Benzing T, Lichter P, Tam W, Brownstein MJ, Bosio A,**
498 **Borkhardt A, Russo JJ, Sander C, Zavolan M, and Tuschl T.** A mammalian microRNA expression atlas
499 based on small RNA library sequencing. *Cell* 129: 1401-1414, 2007.

29. **Latreille M, Hausser J, Stutzer I, Zhang Q, Hastoy B, Gargani S, Kerr-Conte J, Pattou F, Zavolan M, Esguerra JL, Eliasson L, Rulicke T, Rorsman P, and Stoffel M.** MicroRNA-7a regulates pancreatic beta cell function. *The Journal of clinical investigation* 124: 2722-2735, 2014.
30. **Makawita S, Dimitromanolakis A, Soosaipillai A, Soleas I, Chan A, Gallinger S, Haun RS, Blasutig IM, and Diamandis EP.** Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9. *BMC Cancer* 13: 404, 2013.
31. **Marchal S, Givalois L, Verdier JM, and Mestre-Frances N.** Distribution of lithostathine in the mouse lemur brain with aging and Alzheimer's-like pathology. *Neurobiol Aging* 33: 431 e415-425, 2012.
32. **Matozaki T, Sakamoto C, Suzuki T, Chujo S, Matsuda K, Wada K, Nakano O, Konda Y, Nishizaki H, Nagao M, and et al.** Idiopathic chronic calcifying pancreatitis with diabetes mellitus. Analysis of pancreatic stone protein gene. *Digestive diseases and sciences* 38: 963-967, 1993.
33. **Mauro V, Carette D, Chevallier D, Michiels JF, Segretain D, Pointis G, and Senegas-Balas F.** Reg I protein in healthy and seminoma human testis. *Histol Histopathol* 23: 1195-1203, 2008.
34. **Nieto M, Hevia P, Garcia E, Klein D, Alvarez-Cubela S, Bravo-Egana V, Rosero S, Damaris Molano R, Vargas N, Ricordi C, Pileggi A, Diez J, Dominguez-Bendala J, and Pastori RL.** Antisense miR-7 impairs insulin expression in developing pancreas and in cultured pancreatic buds. *Cell transplantation* 21: 1761-1774, 2012.
35. **Parikh A, Stephan AF, and Tzanakakis ES.** Regenerating proteins and their expression, regulation and signaling. *Biomol Concepts* 3: 57-70, 2012.
36. **Park CY, Jeker LT, Carver-Moore K, Oh A, Liu HJ, Cameron R, Richards H, Li Z, Adler D, Yoshinaga Y, Martinez M, Nefadov M, Abbas AK, Weiss A, Lanier LL, de Jong PJ, Bluestone JA, Srivastava D, and McManus MT.** A resource for the conditional ablation of microRNAs in the mouse. *Cell Rep* 1: 385-391, 2012.

523 37. **Perfetti R, Raygada M, Wang Y, Zenilman ME, Egan JM, Denno KM, Sadler TW, and Shuldiner**
524 **AR.** Regenerating (reg) and insulin genes are expressed in prepancreatic mouse embryos. *J Mol Endocrinol* 17:
525 79-88, 1996.

526 38. **Pichler S, Gu W, Hartl D, Gasparoni G, Leidinger P, Keller A, Meese E, Mayhaus M, Hampel H,**
527 **and Riemenschneider M.** The miRNome of Alzheimer's disease: consistent downregulation of the miR-
528 132/212 cluster. *Neurobiol Aging* 50: 167 e161-167 e110, 2017.

529 39. **Radon TP, Massat NJ, Jones R, Alrawashdeh W, Dumartin L, Ennis D, Duffy SW, Kocher HM,**
530 **Pereira SP, Guarner posthumous L, Murta-Nascimento C, Real FX, Malats N, Neoptolemos J, Costello**
531 **E, Greenhalf W, Lemoine NR, and Crnogorac-Jurcevic T.** Identification of a Three-Biomarker Panel in
532 Urine for Early Detection of Pancreatic Adenocarcinoma. *Clin Cancer Res* 21: 3512-3521, 2015.

533 40. **Sanchez D, Baeza N, Blouin R, Devaux C, Grondin G, Mabrouk K, Guy-Crotte O, and Figarella**
534 **C.** Overexpression of the reg gene in non-obese diabetic mouse pancreas during active diabetogenesis is
535 restricted to exocrine tissue. *J Histochem Cytochem* 48: 1401-1410, 2000.

536 41. **Schultz NA, Werner J, Willenbrock H, Roslind A, Giese N, Horn T, Wojdemann M, and Johansen**
537 **JS.** MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma.
538 *Mod Pathol* 25: 1609-1622, 2012.

539 42. **Taylor SC, Berkelman T, Yadav G, and Hammond M.** A defined methodology for reliable
540 quantification of Western blot data. *Mol Biotechnol* 55: 217-226, 2013.

541 43. **Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y, and Okamoto H.** A
542 novel gene activated in regenerating islets. *The Journal of biological chemistry* 263: 2111-2114, 1988.

543 44. **Unno M, Nata K, Noguchi N, Narushima Y, Akiyama T, Ikeda T, Nakagawa K, Takasawa S, and**
544 **Okamoto H.** Production and characterization of Reg knockout mice: reduced proliferation of pancreatic beta-
545 cells in Reg knockout mice. *Diabetes* 51 Suppl 3: S478-483, 2002.

546 45. **Unno M, Yonekura H, Nakagawara K, Watanabe T, Miyashita H, Moriizumi S, Okamoto H, Itoh**
547 **T, and Teraoka H.** Structure, chromosomal localization, and expression of mouse reg genes, reg I and reg II. A

- novel type of reg gene, reg II, exists in the mouse genome. *The Journal of biological chemistry* 268: 15974-15982, 1993.
46. **Wang Y, Liu J, Liu C, Naji A, and Stoffers DA.** MicroRNA-7 regulates the mTOR pathway and proliferation in adult pancreatic beta-cells. *Diabetes* 62: 887-895, 2013.
47. **Wienholds E, Kloosterman WP, Miska E, Alvarez-Saavedra E, Berezikov E, de Bruijn E, Horvitz HR, Kauppinen S, and Plasterk RH.** MicroRNA expression in zebrafish embryonic development. *Science* 309: 310-311, 2005.
48. **Yamaoka T, Yoshino K, Yamada T, Idehara C, Hoque MO, Moritani M, Yoshimoto K, Hata J, and Itakura M.** Diabetes and tumor formation in transgenic mice expressing Reg I. *Biochem Biophys Res Commun* 278: 368-376, 2000.
49. **Zenilman ME, Kim S, Levine BA, Lee C, and Steinberg JJ.** Ectopic expression of reg protein: A marker of colorectal mucosa at risk for neoplasia. *J Gastrointest Surg* 1: 194-201; discussion 201-192, 1997.
50. **Zhang F, and Tzanakakis ES.** Optogenetic regulation of insulin secretion in pancreatic beta-cells. *Sci Rep* 7: 9357, 2017.


Table 1. Primers used in this study (shown in a 5' to 3' orientation).

Gene	Forward primer	Reverse primer	Amplicon size (bp)
<i>Reg1</i>	CTCATGCCTGATCGTCCTGTC	AGCCCAAGTTAAACGGTCTTC	142
<i>Actb</i>	GTGACGTTGACATCCGTAAAGA	GCCGGACTCATCGTACTCC	245
Mir-7*	CGTGGAAGACTAGTGATTTTGTTG	miRNA reverse primer	86
<i>Rnu6</i>	GCAAATTCGTGAAGCGTTCC	miRNA reverse primer	104
miRNA reverse primer		GCATAGACCTGAATGGCGGTAAGGGT GTGGTAGGCGAGACATTTTTTTTTTTT TTTTTTTT	

* The primer is homologous to both Mir7-1 and Mir7-2.

Table 2. List of putative miRNAs targeting (mRNA) *reg1* based on *in silico* analysis.



miRNA	Sequence (3' to 5')	Targeted Positions of <i>reg1</i> 3'UTR
miR-19a/b-3p	AGUCAAAACGUACCUGAAACGUGU	164-171
miR-7a/b-5p	UGUUGUUUUAGUGAUCAGAAGGU	97-103
miR-599-5p	AGAGGAUACAGUAGAAUAGUUU	75-81
miR-665-3p	UCCCUGGAGUCGGAGGACCA	101-107
miR-1197-3p	UCUUCAUCUGGUACACAGGAU	126-132
miR-463-3p	GAUGGAAUAUACCACAGAUAGU	73-79
miR-3101-5p	GAUCGAAAUCAGUUACCAUGG	132-138
miR-669o-5p	UGUAUUUGUACGUGUGUGUUGAU	168-174
miR-3097-5p	ACCUGUGUGUGAAGGGUGGACAC	137-143











Reg1 3'UTR



mmu-miR-7a-5p


mmu-miR-7b-5p











Luc-3'UTR-REG1A

+

+

-

-

Luc-3'UTR-REG1B

-

-

+

+

***miR7* OE**

-

+

-

+

Empty vector

+

-

+

-